Not exact matches
As a result, periods missed due to malnutrition suggest low estrogen, and therefore a
potential for poor
bone growth, which, in turn, compromises
bones and can lead to early hip
fractures in a woman's 30s and to osteoporosis.
The results, appearing in Nature Communications, offer
potential treatment targets for this rare disease, provide important clues about
bone development, and may lead to insights about
fracture healing and osteoporosis.
Potential cardioprotection was based on generally supportive data on lipid levels in intermediate outcome clinical trials, trials in nonhuman primates, and a large body of observational studies suggesting a 40 % to 50 % reduction in risk among users of either estrogen alone or, less frequently, combined estrogen and progestin.2 - 5 Hip
fracture was designated as a secondary outcome, supported by observational data as well as clinical trials showing benefit for
bone mineral density.6, 7 Invasive breast cancer was designated as a primary adverse outcome based on observational data.3, 8 Additional clinical outcomes chosen as secondary outcomes that may plausibly be affected by hormone therapy include other cardiovascular diseases; endometrial, colorectal, and other cancers; and other
fractures.3, 6,9
Regardless of whether a
fracture is displaced, non-displaced, open, or closed, a broken
bone may result in considerable pain, discomfort, and the
potential for permanent physical impairment.
Furthermore, a new safety warning issued by the FDA cautions consumers and medical professionals of a
potential risk of
bone fractures in patients using Invokana.